Last reviewed 2026-04-23 · How we verify

Betamethasone Sodium Phosphate 0.01%

Surface Ophthalmics, Inc. · Phase 2 active Small molecule

Betamethasone Sodium Phosphate 0.01% is a Corticosteroid Small molecule drug developed by Surface Ophthalmics, Inc.. It is currently in Phase 2 development for Treatment of ocular inflammation and uveitis.

Betamethasone sodium phosphate is a corticosteroid that reduces inflammation and suppresses the immune system.

Betamethasone sodium phosphate is a corticosteroid that reduces inflammation and suppresses the immune system. Used for Treatment of ocular inflammation and uveitis.

At a glance

Generic name	Betamethasone Sodium Phosphate 0.01%
Sponsor	Surface Ophthalmics, Inc.
Drug class	Corticosteroid
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	Phase 2

Mechanism of action

It works by inhibiting the production of inflammatory mediators and reducing the activity of immune cells. This leads to a decrease in swelling, redness, and pain in the affected area. Betamethasone sodium phosphate is also used to suppress the immune system in patients with certain autoimmune disorders.

Approved indications

Treatment of ocular inflammation and uveitis

Common side effects

Increased intraocular pressure

Key clinical trials

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Betamethasone Sodium Phosphate 0.01% CI brief — competitive landscape report
Betamethasone Sodium Phosphate 0.01% updates RSS · CI watch RSS
Surface Ophthalmics, Inc. portfolio CI

Frequently asked questions about Betamethasone Sodium Phosphate 0.01%

What is Betamethasone Sodium Phosphate 0.01%?

Betamethasone Sodium Phosphate 0.01% is a Corticosteroid drug developed by Surface Ophthalmics, Inc., indicated for Treatment of ocular inflammation and uveitis.

How does Betamethasone Sodium Phosphate 0.01% work?

Betamethasone sodium phosphate is a corticosteroid that reduces inflammation and suppresses the immune system.

What is Betamethasone Sodium Phosphate 0.01% used for?

Betamethasone Sodium Phosphate 0.01% is indicated for Treatment of ocular inflammation and uveitis.

Who makes Betamethasone Sodium Phosphate 0.01%?

Betamethasone Sodium Phosphate 0.01% is developed by Surface Ophthalmics, Inc. (see full Surface Ophthalmics, Inc. pipeline at /company/surface-ophthalmics-inc).

What drug class is Betamethasone Sodium Phosphate 0.01% in?

Betamethasone Sodium Phosphate 0.01% belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is Betamethasone Sodium Phosphate 0.01% in?

Betamethasone Sodium Phosphate 0.01% is in Phase 2.

What are the side effects of Betamethasone Sodium Phosphate 0.01%?

Common side effects of Betamethasone Sodium Phosphate 0.01% include Increased intraocular pressure.

Drug class: All Corticosteroid drugs
Manufacturer: Surface Ophthalmics, Inc. — full pipeline
Therapeutic area: All drugs in Ophthalmology
Indication: Drugs for Treatment of ocular inflammation and uveitis
Compare: Betamethasone Sodium Phosphate 0.01% vs similar drugs
Pricing: Betamethasone Sodium Phosphate 0.01% cost, discount & access